Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation
This study is designed to evaluate the efficacy and safety of icotinib and pemetrexed-based
first-line induction and maintenance chemotherapy in advanced lung adenocarcinoma with
EGFR-mutation，primary endpoint is progress-free survival，second endpoints include overall
survival, time to progression, and so on.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression Free Survival
A duration from randomization date to disease progression(as defined by RECIST) or death. If a participant are known to have progressed, the time to progression is defined as the time from the date of randomization to the date of progression. Otherwise, a participant will be censored at the last date they are known not to be progressed.
Shi Yuankai, M.D.
Cancer Hospital, Chinese Academy of Medical Sciences
China: Food and Drug Administration